S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
NASDAQ:VALN

Valneva (VALN) Stock Price, News & Analysis

$7.58
-0.55 (-6.77%)
(As of 04/19/2024 08:51 PM ET)
Today's Range
$7.58
$7.97
50-Day Range
$6.63
$8.89
52-Week Range
$6.58
$17.05
Volume
8,500 shs
Average Volume
9,153 shs
Market Capitalization
$526.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.67

Valneva MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
185.8% Upside
$21.67 Price Target
Short Interest
Bearish
0.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of Valneva in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $0.11 to ($1.01) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.09 out of 5 stars

Medical Sector

769th out of 907 stocks

Biotechnology Industry

14th out of 26 stocks

VALN stock logo

About Valneva Stock (NASDAQ:VALN)

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

VALN Stock Price History

VALN Stock News Headlines

Valneva (NASDAQ:VALN) Stock Price Down 3.9%
Valneva (NASDAQ:VALN) Shares Gap Up to $8.04
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Valneva SE (VALN) Q4 2023 Earnings Call Transcript
What Analysts Are Saying About Valneva Stock
See More Headlines
Receive VALN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Valneva and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/20/2024
Today
4/22/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:VALN
Fax
N/A
Employees
676
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.67
High Stock Price Target
$26.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+185.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-109,780,000.00
Pretax Margin
-64.16%

Debt

Sales & Book Value

Annual Sales
$165.52 million
Book Value
$2.00 per share

Miscellaneous

Free Float
59,100,000
Market Cap
$526.51 million
Optionable
Not Optionable
Beta
2.25
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Thomas Lingelbach (Age 61)
    President, CEO & Director
    Comp: $981.08k
  • Mr. Peter Buhler (Age 53)
    Chief Financial Officer
    Comp: $596.22k
  • Mr. Frederic Jacotot (Age 60)
    VP of Legal & IP, General Counsel, and Corporate Secretary
    Comp: $325.62k
  • Mr. Franck Grimaud MBA (Age 57)
    Chief Business Officer
    Comp: $428.19k
  • Dr. Juan-Carlos Jaramillo M.D. (Age 52)
    Chief Medical Officer
    Comp: $575.87k
  • Ms. Dipal Patel (Age 49)
    Chief Commercial Officer
    Comp: $551.33k
  • Mr. Vincent Dequenne (Age 57)
    Chief Operating Officer
  • Mr. Joshua Drumm Ph.D.
    Vice President of Investor Relations
  • Ms. Laetitia Bachelot-Fontaine
    VP of Global Communications & European Investor Relations
  • Ms. Petra Pesendorfer (Age 38)
    Chief People Officer

VALN Stock Analysis - Frequently Asked Questions

Should I buy or sell Valneva stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Valneva in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VALN shares.
View VALN analyst ratings
or view top-rated stocks.

What is Valneva's stock price target for 2024?

3 brokerages have issued 1 year price targets for Valneva's stock. Their VALN share price targets range from $17.00 to $26.00. On average, they predict the company's stock price to reach $21.67 in the next twelve months. This suggests a possible upside of 185.8% from the stock's current price.
View analysts price targets for VALN
or view top-rated stocks among Wall Street analysts.

How have VALN shares performed in 2024?

Valneva's stock was trading at $10.37 at the beginning of 2024. Since then, VALN shares have decreased by 26.9% and is now trading at $7.58.
View the best growth stocks for 2024 here
.

When is Valneva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our VALN earnings forecast
.

How were Valneva's earnings last quarter?

Valneva SE (NASDAQ:VALN) posted its quarterly earnings results on Wednesday, March, 20th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by $0.70. The firm had revenue of $45.12 million for the quarter, compared to the consensus estimate of $45.06 million. Valneva had a negative net margin of 65.99% and a negative trailing twelve-month return on equity of 59.48%.

What guidance has Valneva issued on next quarter's earnings?

Valneva issued an update on its FY 2024 earnings guidance on Wednesday, March, 20th. The company provided EPS guidance of for the period. The company issued revenue guidance of $172.2 million-$193.8 million, compared to the consensus revenue estimate of $245.0 million.

When did Valneva IPO?

Valneva (VALN) raised $99 million in an IPO on Thursday, May 6th 2021. The company issued 3,500,000 shares at $28.24 per share. Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. acted as the underwriters for the IPO.

How do I buy shares of Valneva?

Shares of VALN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VALN) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners